Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer
Approximatively 8–15% of patients with metastatic colorectal cancer (mCRC) harbor mutation in BRAF gene. Recent advances in molecular biology enabled a better knowledge of the molecular heterogeneity within BRAF mutant (BRAFMT) CRCs, including high rate of overlapping with MSI-H status and detection...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Rodriquenz, Maria Grazia [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2022transfer abstract |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: miR-214 in stroma cells and tumor progression - Dettori, D. ELSEVIER, 2016, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:173 ; year:2022 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.critrevonc.2022.103657 |
|---|
| Katalog-ID: |
ELV05749777X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV05749777X | ||
| 003 | DE-627 | ||
| 005 | 20230626045229.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220808s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.critrevonc.2022.103657 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001749.pica |
| 035 | |a (DE-627)ELV05749777X | ||
| 035 | |a (ELSEVIER)S1040-8428(22)00081-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.52 |2 bkl | ||
| 100 | 1 | |a Rodriquenz, Maria Grazia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer |
| 264 | 1 | |c 2022transfer abstract | |
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Approximatively 8–15% of patients with metastatic colorectal cancer (mCRC) harbor mutation in BRAF gene. Recent advances in molecular biology enabled a better knowledge of the molecular heterogeneity within BRAF mutant (BRAFMT) CRCs, including high rate of overlapping with MSI-H status and detection of non-V600E mutations related to more favorable behavior. Treatment armamentarium has been rapidly growing in this subgroup and includes targeted combinations and immunotherapy for concomitant MSI-H patients, thereby making BRAFMT mCRC an innovative model for precision oncology. Nevertheless, duration of responses to targeted strategies remains unsatisfactory due to the development of secondary resistance, which is currently the field of major clinical research on BRAFMT mCRC. This review explores the molecular, clinical and therapeutic landscape of BRAFMT mCRC as well as an update on current treatment strategies and future perspectives in light of the heterogeneity of BRAF-mutated disease. Furthermore, a novel treatment algorithm for BRAFMT mCRC will be proposed. | ||
| 520 | |a Approximatively 8–15% of patients with metastatic colorectal cancer (mCRC) harbor mutation in BRAF gene. Recent advances in molecular biology enabled a better knowledge of the molecular heterogeneity within BRAF mutant (BRAFMT) CRCs, including high rate of overlapping with MSI-H status and detection of non-V600E mutations related to more favorable behavior. Treatment armamentarium has been rapidly growing in this subgroup and includes targeted combinations and immunotherapy for concomitant MSI-H patients, thereby making BRAFMT mCRC an innovative model for precision oncology. Nevertheless, duration of responses to targeted strategies remains unsatisfactory due to the development of secondary resistance, which is currently the field of major clinical research on BRAFMT mCRC. This review explores the molecular, clinical and therapeutic landscape of BRAFMT mCRC as well as an update on current treatment strategies and future perspectives in light of the heterogeneity of BRAF-mutated disease. Furthermore, a novel treatment algorithm for BRAFMT mCRC will be proposed. | ||
| 650 | 7 | |a FDA |2 Elsevier | |
| 650 | 7 | |a RCT |2 Elsevier | |
| 650 | 7 | |a PS |2 Elsevier | |
| 650 | 7 | |a WES |2 Elsevier | |
| 650 | 7 | |a PTEN |2 Elsevier | |
| 650 | 7 | |a CARG |2 Elsevier | |
| 650 | 7 | |a ctDNA |2 Elsevier | |
| 650 | 7 | |a ORR |2 Elsevier | |
| 650 | 7 | |a QoL |2 Elsevier | |
| 650 | 7 | |a BRAFMT |2 Elsevier | |
| 650 | 7 | |a CRASH |2 Elsevier | |
| 650 | 7 | |a PI3K |2 Elsevier | |
| 650 | 7 | |a mCRC |2 Elsevier | |
| 650 | 7 | |a cfDNA |2 Elsevier | |
| 650 | 7 | |a CIMP |2 Elsevier | |
| 650 | 7 | |a WTS |2 Elsevier | |
| 650 | 7 | |a EMA |2 Elsevier | |
| 650 | 7 | |a RAC1 |2 Elsevier | |
| 650 | 7 | |a BRAFi |2 Elsevier | |
| 650 | 7 | |a PFS |2 Elsevier | |
| 650 | 7 | |a dMMR |2 Elsevier | |
| 650 | 7 | |a RNF43 |2 Elsevier | |
| 650 | 7 | |a cORR |2 Elsevier | |
| 650 | 7 | |a AE |2 Elsevier | |
| 650 | 7 | |a OS |2 Elsevier | |
| 650 | 7 | |a DOR |2 Elsevier | |
| 650 | 7 | |a CMS |2 Elsevier | |
| 650 | 7 | |a MSS |2 Elsevier | |
| 650 | 7 | |a EMT |2 Elsevier | |
| 650 | 7 | |a RNAseq |2 Elsevier | |
| 650 | 7 | |a ICI |2 Elsevier | |
| 650 | 7 | |a DCR |2 Elsevier | |
| 650 | 7 | |a MEK |2 Elsevier | |
| 650 | 7 | |a MEKi |2 Elsevier | |
| 650 | 7 | |a MAF |2 Elsevier | |
| 650 | 7 | |a TKI |2 Elsevier | |
| 650 | 7 | |a CDK4 |2 Elsevier | |
| 650 | 7 | |a CRC |2 Elsevier | |
| 650 | 7 | |a mAbs |2 Elsevier | |
| 650 | 7 | |a NF-1 |2 Elsevier | |
| 650 | 7 | |a NGS |2 Elsevier | |
| 650 | 7 | |a MET |2 Elsevier | |
| 700 | 1 | |a Ciardiello, Davide |4 oth | |
| 700 | 1 | |a Latiano, Tiziana Pia |4 oth | |
| 700 | 1 | |a Maiorano, Brigida Anna |4 oth | |
| 700 | 1 | |a Martinelli, Erika |4 oth | |
| 700 | 1 | |a Silvestris, Nicola |4 oth | |
| 700 | 1 | |a Ciardiello, Fortunato |4 oth | |
| 700 | 1 | |a Maiello, Evaristo |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Dettori, D. ELSEVIER |t miR-214 in stroma cells and tumor progression |d 2016 |g Amsterdam [u.a.] |w (DE-627)ELV019637179 |
| 773 | 1 | 8 | |g volume:173 |g year:2022 |g pages:0 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.critrevonc.2022.103657 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_100 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2015 | ||
| 912 | |a GBV_ILN_2016 | ||
| 912 | |a GBV_ILN_2048 | ||
| 936 | b | k | |a 44.52 |j Therapie |x Medizin |q VZ |
| 951 | |a AR | ||
| 952 | |d 173 |j 2022 |h 0 | ||
| author_variant |
m g r mg mgr |
|---|---|
| matchkey_str |
rodriquenzmariagraziaciardiellodavidelat:2022----:xlrnbooiahtrgniynipiainonvlramnprdgibamt |
| hierarchy_sort_str |
2022transfer abstract |
| bklnumber |
44.52 |
| publishDate |
2022 |
| allfields |
10.1016/j.critrevonc.2022.103657 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001749.pica (DE-627)ELV05749777X (ELSEVIER)S1040-8428(22)00081-6 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.52 bkl Rodriquenz, Maria Grazia verfasserin aut Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer 2022transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Approximatively 8–15% of patients with metastatic colorectal cancer (mCRC) harbor mutation in BRAF gene. Recent advances in molecular biology enabled a better knowledge of the molecular heterogeneity within BRAF mutant (BRAFMT) CRCs, including high rate of overlapping with MSI-H status and detection of non-V600E mutations related to more favorable behavior. Treatment armamentarium has been rapidly growing in this subgroup and includes targeted combinations and immunotherapy for concomitant MSI-H patients, thereby making BRAFMT mCRC an innovative model for precision oncology. Nevertheless, duration of responses to targeted strategies remains unsatisfactory due to the development of secondary resistance, which is currently the field of major clinical research on BRAFMT mCRC. This review explores the molecular, clinical and therapeutic landscape of BRAFMT mCRC as well as an update on current treatment strategies and future perspectives in light of the heterogeneity of BRAF-mutated disease. Furthermore, a novel treatment algorithm for BRAFMT mCRC will be proposed. Approximatively 8–15% of patients with metastatic colorectal cancer (mCRC) harbor mutation in BRAF gene. Recent advances in molecular biology enabled a better knowledge of the molecular heterogeneity within BRAF mutant (BRAFMT) CRCs, including high rate of overlapping with MSI-H status and detection of non-V600E mutations related to more favorable behavior. Treatment armamentarium has been rapidly growing in this subgroup and includes targeted combinations and immunotherapy for concomitant MSI-H patients, thereby making BRAFMT mCRC an innovative model for precision oncology. Nevertheless, duration of responses to targeted strategies remains unsatisfactory due to the development of secondary resistance, which is currently the field of major clinical research on BRAFMT mCRC. This review explores the molecular, clinical and therapeutic landscape of BRAFMT mCRC as well as an update on current treatment strategies and future perspectives in light of the heterogeneity of BRAF-mutated disease. Furthermore, a novel treatment algorithm for BRAFMT mCRC will be proposed. FDA Elsevier RCT Elsevier PS Elsevier WES Elsevier PTEN Elsevier CARG Elsevier ctDNA Elsevier ORR Elsevier QoL Elsevier BRAFMT Elsevier CRASH Elsevier PI3K Elsevier mCRC Elsevier cfDNA Elsevier CIMP Elsevier WTS Elsevier EMA Elsevier RAC1 Elsevier BRAFi Elsevier PFS Elsevier dMMR Elsevier RNF43 Elsevier cORR Elsevier AE Elsevier OS Elsevier DOR Elsevier CMS Elsevier MSS Elsevier EMT Elsevier RNAseq Elsevier ICI Elsevier DCR Elsevier MEK Elsevier MEKi Elsevier MAF Elsevier TKI Elsevier CDK4 Elsevier CRC Elsevier mAbs Elsevier NF-1 Elsevier NGS Elsevier MET Elsevier Ciardiello, Davide oth Latiano, Tiziana Pia oth Maiorano, Brigida Anna oth Martinelli, Erika oth Silvestris, Nicola oth Ciardiello, Fortunato oth Maiello, Evaristo oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:173 year:2022 pages:0 https://doi.org/10.1016/j.critrevonc.2022.103657 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 173 2022 0 |
| spelling |
10.1016/j.critrevonc.2022.103657 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001749.pica (DE-627)ELV05749777X (ELSEVIER)S1040-8428(22)00081-6 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.52 bkl Rodriquenz, Maria Grazia verfasserin aut Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer 2022transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Approximatively 8–15% of patients with metastatic colorectal cancer (mCRC) harbor mutation in BRAF gene. Recent advances in molecular biology enabled a better knowledge of the molecular heterogeneity within BRAF mutant (BRAFMT) CRCs, including high rate of overlapping with MSI-H status and detection of non-V600E mutations related to more favorable behavior. Treatment armamentarium has been rapidly growing in this subgroup and includes targeted combinations and immunotherapy for concomitant MSI-H patients, thereby making BRAFMT mCRC an innovative model for precision oncology. Nevertheless, duration of responses to targeted strategies remains unsatisfactory due to the development of secondary resistance, which is currently the field of major clinical research on BRAFMT mCRC. This review explores the molecular, clinical and therapeutic landscape of BRAFMT mCRC as well as an update on current treatment strategies and future perspectives in light of the heterogeneity of BRAF-mutated disease. Furthermore, a novel treatment algorithm for BRAFMT mCRC will be proposed. Approximatively 8–15% of patients with metastatic colorectal cancer (mCRC) harbor mutation in BRAF gene. Recent advances in molecular biology enabled a better knowledge of the molecular heterogeneity within BRAF mutant (BRAFMT) CRCs, including high rate of overlapping with MSI-H status and detection of non-V600E mutations related to more favorable behavior. Treatment armamentarium has been rapidly growing in this subgroup and includes targeted combinations and immunotherapy for concomitant MSI-H patients, thereby making BRAFMT mCRC an innovative model for precision oncology. Nevertheless, duration of responses to targeted strategies remains unsatisfactory due to the development of secondary resistance, which is currently the field of major clinical research on BRAFMT mCRC. This review explores the molecular, clinical and therapeutic landscape of BRAFMT mCRC as well as an update on current treatment strategies and future perspectives in light of the heterogeneity of BRAF-mutated disease. Furthermore, a novel treatment algorithm for BRAFMT mCRC will be proposed. FDA Elsevier RCT Elsevier PS Elsevier WES Elsevier PTEN Elsevier CARG Elsevier ctDNA Elsevier ORR Elsevier QoL Elsevier BRAFMT Elsevier CRASH Elsevier PI3K Elsevier mCRC Elsevier cfDNA Elsevier CIMP Elsevier WTS Elsevier EMA Elsevier RAC1 Elsevier BRAFi Elsevier PFS Elsevier dMMR Elsevier RNF43 Elsevier cORR Elsevier AE Elsevier OS Elsevier DOR Elsevier CMS Elsevier MSS Elsevier EMT Elsevier RNAseq Elsevier ICI Elsevier DCR Elsevier MEK Elsevier MEKi Elsevier MAF Elsevier TKI Elsevier CDK4 Elsevier CRC Elsevier mAbs Elsevier NF-1 Elsevier NGS Elsevier MET Elsevier Ciardiello, Davide oth Latiano, Tiziana Pia oth Maiorano, Brigida Anna oth Martinelli, Erika oth Silvestris, Nicola oth Ciardiello, Fortunato oth Maiello, Evaristo oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:173 year:2022 pages:0 https://doi.org/10.1016/j.critrevonc.2022.103657 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 173 2022 0 |
| allfields_unstemmed |
10.1016/j.critrevonc.2022.103657 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001749.pica (DE-627)ELV05749777X (ELSEVIER)S1040-8428(22)00081-6 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.52 bkl Rodriquenz, Maria Grazia verfasserin aut Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer 2022transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Approximatively 8–15% of patients with metastatic colorectal cancer (mCRC) harbor mutation in BRAF gene. Recent advances in molecular biology enabled a better knowledge of the molecular heterogeneity within BRAF mutant (BRAFMT) CRCs, including high rate of overlapping with MSI-H status and detection of non-V600E mutations related to more favorable behavior. Treatment armamentarium has been rapidly growing in this subgroup and includes targeted combinations and immunotherapy for concomitant MSI-H patients, thereby making BRAFMT mCRC an innovative model for precision oncology. Nevertheless, duration of responses to targeted strategies remains unsatisfactory due to the development of secondary resistance, which is currently the field of major clinical research on BRAFMT mCRC. This review explores the molecular, clinical and therapeutic landscape of BRAFMT mCRC as well as an update on current treatment strategies and future perspectives in light of the heterogeneity of BRAF-mutated disease. Furthermore, a novel treatment algorithm for BRAFMT mCRC will be proposed. Approximatively 8–15% of patients with metastatic colorectal cancer (mCRC) harbor mutation in BRAF gene. Recent advances in molecular biology enabled a better knowledge of the molecular heterogeneity within BRAF mutant (BRAFMT) CRCs, including high rate of overlapping with MSI-H status and detection of non-V600E mutations related to more favorable behavior. Treatment armamentarium has been rapidly growing in this subgroup and includes targeted combinations and immunotherapy for concomitant MSI-H patients, thereby making BRAFMT mCRC an innovative model for precision oncology. Nevertheless, duration of responses to targeted strategies remains unsatisfactory due to the development of secondary resistance, which is currently the field of major clinical research on BRAFMT mCRC. This review explores the molecular, clinical and therapeutic landscape of BRAFMT mCRC as well as an update on current treatment strategies and future perspectives in light of the heterogeneity of BRAF-mutated disease. Furthermore, a novel treatment algorithm for BRAFMT mCRC will be proposed. FDA Elsevier RCT Elsevier PS Elsevier WES Elsevier PTEN Elsevier CARG Elsevier ctDNA Elsevier ORR Elsevier QoL Elsevier BRAFMT Elsevier CRASH Elsevier PI3K Elsevier mCRC Elsevier cfDNA Elsevier CIMP Elsevier WTS Elsevier EMA Elsevier RAC1 Elsevier BRAFi Elsevier PFS Elsevier dMMR Elsevier RNF43 Elsevier cORR Elsevier AE Elsevier OS Elsevier DOR Elsevier CMS Elsevier MSS Elsevier EMT Elsevier RNAseq Elsevier ICI Elsevier DCR Elsevier MEK Elsevier MEKi Elsevier MAF Elsevier TKI Elsevier CDK4 Elsevier CRC Elsevier mAbs Elsevier NF-1 Elsevier NGS Elsevier MET Elsevier Ciardiello, Davide oth Latiano, Tiziana Pia oth Maiorano, Brigida Anna oth Martinelli, Erika oth Silvestris, Nicola oth Ciardiello, Fortunato oth Maiello, Evaristo oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:173 year:2022 pages:0 https://doi.org/10.1016/j.critrevonc.2022.103657 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 173 2022 0 |
| allfieldsGer |
10.1016/j.critrevonc.2022.103657 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001749.pica (DE-627)ELV05749777X (ELSEVIER)S1040-8428(22)00081-6 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.52 bkl Rodriquenz, Maria Grazia verfasserin aut Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer 2022transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Approximatively 8–15% of patients with metastatic colorectal cancer (mCRC) harbor mutation in BRAF gene. Recent advances in molecular biology enabled a better knowledge of the molecular heterogeneity within BRAF mutant (BRAFMT) CRCs, including high rate of overlapping with MSI-H status and detection of non-V600E mutations related to more favorable behavior. Treatment armamentarium has been rapidly growing in this subgroup and includes targeted combinations and immunotherapy for concomitant MSI-H patients, thereby making BRAFMT mCRC an innovative model for precision oncology. Nevertheless, duration of responses to targeted strategies remains unsatisfactory due to the development of secondary resistance, which is currently the field of major clinical research on BRAFMT mCRC. This review explores the molecular, clinical and therapeutic landscape of BRAFMT mCRC as well as an update on current treatment strategies and future perspectives in light of the heterogeneity of BRAF-mutated disease. Furthermore, a novel treatment algorithm for BRAFMT mCRC will be proposed. Approximatively 8–15% of patients with metastatic colorectal cancer (mCRC) harbor mutation in BRAF gene. Recent advances in molecular biology enabled a better knowledge of the molecular heterogeneity within BRAF mutant (BRAFMT) CRCs, including high rate of overlapping with MSI-H status and detection of non-V600E mutations related to more favorable behavior. Treatment armamentarium has been rapidly growing in this subgroup and includes targeted combinations and immunotherapy for concomitant MSI-H patients, thereby making BRAFMT mCRC an innovative model for precision oncology. Nevertheless, duration of responses to targeted strategies remains unsatisfactory due to the development of secondary resistance, which is currently the field of major clinical research on BRAFMT mCRC. This review explores the molecular, clinical and therapeutic landscape of BRAFMT mCRC as well as an update on current treatment strategies and future perspectives in light of the heterogeneity of BRAF-mutated disease. Furthermore, a novel treatment algorithm for BRAFMT mCRC will be proposed. FDA Elsevier RCT Elsevier PS Elsevier WES Elsevier PTEN Elsevier CARG Elsevier ctDNA Elsevier ORR Elsevier QoL Elsevier BRAFMT Elsevier CRASH Elsevier PI3K Elsevier mCRC Elsevier cfDNA Elsevier CIMP Elsevier WTS Elsevier EMA Elsevier RAC1 Elsevier BRAFi Elsevier PFS Elsevier dMMR Elsevier RNF43 Elsevier cORR Elsevier AE Elsevier OS Elsevier DOR Elsevier CMS Elsevier MSS Elsevier EMT Elsevier RNAseq Elsevier ICI Elsevier DCR Elsevier MEK Elsevier MEKi Elsevier MAF Elsevier TKI Elsevier CDK4 Elsevier CRC Elsevier mAbs Elsevier NF-1 Elsevier NGS Elsevier MET Elsevier Ciardiello, Davide oth Latiano, Tiziana Pia oth Maiorano, Brigida Anna oth Martinelli, Erika oth Silvestris, Nicola oth Ciardiello, Fortunato oth Maiello, Evaristo oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:173 year:2022 pages:0 https://doi.org/10.1016/j.critrevonc.2022.103657 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 173 2022 0 |
| allfieldsSound |
10.1016/j.critrevonc.2022.103657 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001749.pica (DE-627)ELV05749777X (ELSEVIER)S1040-8428(22)00081-6 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.52 bkl Rodriquenz, Maria Grazia verfasserin aut Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer 2022transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Approximatively 8–15% of patients with metastatic colorectal cancer (mCRC) harbor mutation in BRAF gene. Recent advances in molecular biology enabled a better knowledge of the molecular heterogeneity within BRAF mutant (BRAFMT) CRCs, including high rate of overlapping with MSI-H status and detection of non-V600E mutations related to more favorable behavior. Treatment armamentarium has been rapidly growing in this subgroup and includes targeted combinations and immunotherapy for concomitant MSI-H patients, thereby making BRAFMT mCRC an innovative model for precision oncology. Nevertheless, duration of responses to targeted strategies remains unsatisfactory due to the development of secondary resistance, which is currently the field of major clinical research on BRAFMT mCRC. This review explores the molecular, clinical and therapeutic landscape of BRAFMT mCRC as well as an update on current treatment strategies and future perspectives in light of the heterogeneity of BRAF-mutated disease. Furthermore, a novel treatment algorithm for BRAFMT mCRC will be proposed. Approximatively 8–15% of patients with metastatic colorectal cancer (mCRC) harbor mutation in BRAF gene. Recent advances in molecular biology enabled a better knowledge of the molecular heterogeneity within BRAF mutant (BRAFMT) CRCs, including high rate of overlapping with MSI-H status and detection of non-V600E mutations related to more favorable behavior. Treatment armamentarium has been rapidly growing in this subgroup and includes targeted combinations and immunotherapy for concomitant MSI-H patients, thereby making BRAFMT mCRC an innovative model for precision oncology. Nevertheless, duration of responses to targeted strategies remains unsatisfactory due to the development of secondary resistance, which is currently the field of major clinical research on BRAFMT mCRC. This review explores the molecular, clinical and therapeutic landscape of BRAFMT mCRC as well as an update on current treatment strategies and future perspectives in light of the heterogeneity of BRAF-mutated disease. Furthermore, a novel treatment algorithm for BRAFMT mCRC will be proposed. FDA Elsevier RCT Elsevier PS Elsevier WES Elsevier PTEN Elsevier CARG Elsevier ctDNA Elsevier ORR Elsevier QoL Elsevier BRAFMT Elsevier CRASH Elsevier PI3K Elsevier mCRC Elsevier cfDNA Elsevier CIMP Elsevier WTS Elsevier EMA Elsevier RAC1 Elsevier BRAFi Elsevier PFS Elsevier dMMR Elsevier RNF43 Elsevier cORR Elsevier AE Elsevier OS Elsevier DOR Elsevier CMS Elsevier MSS Elsevier EMT Elsevier RNAseq Elsevier ICI Elsevier DCR Elsevier MEK Elsevier MEKi Elsevier MAF Elsevier TKI Elsevier CDK4 Elsevier CRC Elsevier mAbs Elsevier NF-1 Elsevier NGS Elsevier MET Elsevier Ciardiello, Davide oth Latiano, Tiziana Pia oth Maiorano, Brigida Anna oth Martinelli, Erika oth Silvestris, Nicola oth Ciardiello, Fortunato oth Maiello, Evaristo oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:173 year:2022 pages:0 https://doi.org/10.1016/j.critrevonc.2022.103657 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 173 2022 0 |
| language |
English |
| source |
Enthalten in miR-214 in stroma cells and tumor progression Amsterdam [u.a.] volume:173 year:2022 pages:0 |
| sourceStr |
Enthalten in miR-214 in stroma cells and tumor progression Amsterdam [u.a.] volume:173 year:2022 pages:0 |
| format_phy_str_mv |
Article |
| bklname |
Therapie |
| institution |
findex.gbv.de |
| topic_facet |
FDA RCT PS WES PTEN CARG ctDNA ORR QoL BRAFMT CRASH PI3K mCRC cfDNA CIMP WTS EMA RAC1 BRAFi PFS dMMR RNF43 cORR AE OS DOR CMS MSS EMT RNAseq ICI DCR MEK MEKi MAF TKI CDK4 CRC mAbs NF-1 NGS MET |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
miR-214 in stroma cells and tumor progression |
| authorswithroles_txt_mv |
Rodriquenz, Maria Grazia @@aut@@ Ciardiello, Davide @@oth@@ Latiano, Tiziana Pia @@oth@@ Maiorano, Brigida Anna @@oth@@ Martinelli, Erika @@oth@@ Silvestris, Nicola @@oth@@ Ciardiello, Fortunato @@oth@@ Maiello, Evaristo @@oth@@ |
| publishDateDaySort_date |
2022-01-01T00:00:00Z |
| hierarchy_top_id |
ELV019637179 |
| dewey-sort |
3610 |
| id |
ELV05749777X |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV05749777X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626045229.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220808s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.critrevonc.2022.103657</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001749.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV05749777X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1040-8428(22)00081-6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Rodriquenz, Maria Grazia</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022transfer abstract</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Approximatively 8–15% of patients with metastatic colorectal cancer (mCRC) harbor mutation in BRAF gene. Recent advances in molecular biology enabled a better knowledge of the molecular heterogeneity within BRAF mutant (BRAFMT) CRCs, including high rate of overlapping with MSI-H status and detection of non-V600E mutations related to more favorable behavior. Treatment armamentarium has been rapidly growing in this subgroup and includes targeted combinations and immunotherapy for concomitant MSI-H patients, thereby making BRAFMT mCRC an innovative model for precision oncology. Nevertheless, duration of responses to targeted strategies remains unsatisfactory due to the development of secondary resistance, which is currently the field of major clinical research on BRAFMT mCRC. This review explores the molecular, clinical and therapeutic landscape of BRAFMT mCRC as well as an update on current treatment strategies and future perspectives in light of the heterogeneity of BRAF-mutated disease. Furthermore, a novel treatment algorithm for BRAFMT mCRC will be proposed.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Approximatively 8–15% of patients with metastatic colorectal cancer (mCRC) harbor mutation in BRAF gene. Recent advances in molecular biology enabled a better knowledge of the molecular heterogeneity within BRAF mutant (BRAFMT) CRCs, including high rate of overlapping with MSI-H status and detection of non-V600E mutations related to more favorable behavior. Treatment armamentarium has been rapidly growing in this subgroup and includes targeted combinations and immunotherapy for concomitant MSI-H patients, thereby making BRAFMT mCRC an innovative model for precision oncology. Nevertheless, duration of responses to targeted strategies remains unsatisfactory due to the development of secondary resistance, which is currently the field of major clinical research on BRAFMT mCRC. This review explores the molecular, clinical and therapeutic landscape of BRAFMT mCRC as well as an update on current treatment strategies and future perspectives in light of the heterogeneity of BRAF-mutated disease. Furthermore, a novel treatment algorithm for BRAFMT mCRC will be proposed.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">FDA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RCT</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">WES</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PTEN</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CARG</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ctDNA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ORR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">QoL</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BRAFMT</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CRASH</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PI3K</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">mCRC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">cfDNA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CIMP</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">WTS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">EMA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RAC1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BRAFi</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PFS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">dMMR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RNF43</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">cORR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">AE</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">OS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">DOR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CMS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MSS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">EMT</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RNAseq</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ICI</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">DCR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEK</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEKi</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MAF</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">TKI</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CDK4</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CRC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">mAbs</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NF-1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NGS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MET</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ciardiello, Davide</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Latiano, Tiziana Pia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Maiorano, Brigida Anna</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Martinelli, Erika</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Silvestris, Nicola</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ciardiello, Fortunato</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Maiello, Evaristo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Dettori, D. ELSEVIER</subfield><subfield code="t">miR-214 in stroma cells and tumor progression</subfield><subfield code="d">2016</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV019637179</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:173</subfield><subfield code="g">year:2022</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.critrevonc.2022.103657</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2016</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.52</subfield><subfield code="j">Therapie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">173</subfield><subfield code="j">2022</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| author |
Rodriquenz, Maria Grazia |
| spellingShingle |
Rodriquenz, Maria Grazia ddc 610 bkl 44.52 Elsevier FDA Elsevier RCT Elsevier PS Elsevier WES Elsevier PTEN Elsevier CARG Elsevier ctDNA Elsevier ORR Elsevier QoL Elsevier BRAFMT Elsevier CRASH Elsevier PI3K Elsevier mCRC Elsevier cfDNA Elsevier CIMP Elsevier WTS Elsevier EMA Elsevier RAC1 Elsevier BRAFi Elsevier PFS Elsevier dMMR Elsevier RNF43 Elsevier cORR Elsevier AE Elsevier OS Elsevier DOR Elsevier CMS Elsevier MSS Elsevier EMT Elsevier RNAseq Elsevier ICI Elsevier DCR Elsevier MEK Elsevier MEKi Elsevier MAF Elsevier TKI Elsevier CDK4 Elsevier CRC Elsevier mAbs Elsevier NF-1 Elsevier NGS Elsevier MET Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer |
| authorStr |
Rodriquenz, Maria Grazia |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV019637179 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 44.52 bkl Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer FDA Elsevier RCT Elsevier PS Elsevier WES Elsevier PTEN Elsevier CARG Elsevier ctDNA Elsevier ORR Elsevier QoL Elsevier BRAFMT Elsevier CRASH Elsevier PI3K Elsevier mCRC Elsevier cfDNA Elsevier CIMP Elsevier WTS Elsevier EMA Elsevier RAC1 Elsevier BRAFi Elsevier PFS Elsevier dMMR Elsevier RNF43 Elsevier cORR Elsevier AE Elsevier OS Elsevier DOR Elsevier CMS Elsevier MSS Elsevier EMT Elsevier RNAseq Elsevier ICI Elsevier DCR Elsevier MEK Elsevier MEKi Elsevier MAF Elsevier TKI Elsevier CDK4 Elsevier CRC Elsevier mAbs Elsevier NF-1 Elsevier NGS Elsevier MET Elsevier |
| topic |
ddc 610 bkl 44.52 Elsevier FDA Elsevier RCT Elsevier PS Elsevier WES Elsevier PTEN Elsevier CARG Elsevier ctDNA Elsevier ORR Elsevier QoL Elsevier BRAFMT Elsevier CRASH Elsevier PI3K Elsevier mCRC Elsevier cfDNA Elsevier CIMP Elsevier WTS Elsevier EMA Elsevier RAC1 Elsevier BRAFi Elsevier PFS Elsevier dMMR Elsevier RNF43 Elsevier cORR Elsevier AE Elsevier OS Elsevier DOR Elsevier CMS Elsevier MSS Elsevier EMT Elsevier RNAseq Elsevier ICI Elsevier DCR Elsevier MEK Elsevier MEKi Elsevier MAF Elsevier TKI Elsevier CDK4 Elsevier CRC Elsevier mAbs Elsevier NF-1 Elsevier NGS Elsevier MET |
| topic_unstemmed |
ddc 610 bkl 44.52 Elsevier FDA Elsevier RCT Elsevier PS Elsevier WES Elsevier PTEN Elsevier CARG Elsevier ctDNA Elsevier ORR Elsevier QoL Elsevier BRAFMT Elsevier CRASH Elsevier PI3K Elsevier mCRC Elsevier cfDNA Elsevier CIMP Elsevier WTS Elsevier EMA Elsevier RAC1 Elsevier BRAFi Elsevier PFS Elsevier dMMR Elsevier RNF43 Elsevier cORR Elsevier AE Elsevier OS Elsevier DOR Elsevier CMS Elsevier MSS Elsevier EMT Elsevier RNAseq Elsevier ICI Elsevier DCR Elsevier MEK Elsevier MEKi Elsevier MAF Elsevier TKI Elsevier CDK4 Elsevier CRC Elsevier mAbs Elsevier NF-1 Elsevier NGS Elsevier MET |
| topic_browse |
ddc 610 bkl 44.52 Elsevier FDA Elsevier RCT Elsevier PS Elsevier WES Elsevier PTEN Elsevier CARG Elsevier ctDNA Elsevier ORR Elsevier QoL Elsevier BRAFMT Elsevier CRASH Elsevier PI3K Elsevier mCRC Elsevier cfDNA Elsevier CIMP Elsevier WTS Elsevier EMA Elsevier RAC1 Elsevier BRAFi Elsevier PFS Elsevier dMMR Elsevier RNF43 Elsevier cORR Elsevier AE Elsevier OS Elsevier DOR Elsevier CMS Elsevier MSS Elsevier EMT Elsevier RNAseq Elsevier ICI Elsevier DCR Elsevier MEK Elsevier MEKi Elsevier MAF Elsevier TKI Elsevier CDK4 Elsevier CRC Elsevier mAbs Elsevier NF-1 Elsevier NGS Elsevier MET |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
d c dc t p l tp tpl b a m ba bam e m em n s ns f c fc e m em |
| hierarchy_parent_title |
miR-214 in stroma cells and tumor progression |
| hierarchy_parent_id |
ELV019637179 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
miR-214 in stroma cells and tumor progression |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV019637179 |
| title |
Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer |
| ctrlnum |
(DE-627)ELV05749777X (ELSEVIER)S1040-8428(22)00081-6 |
| title_full |
Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer |
| author_sort |
Rodriquenz, Maria Grazia |
| journal |
miR-214 in stroma cells and tumor progression |
| journalStr |
miR-214 in stroma cells and tumor progression |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2022 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Rodriquenz, Maria Grazia |
| container_volume |
173 |
| class |
610 VZ 44.52 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Rodriquenz, Maria Grazia |
| doi_str_mv |
10.1016/j.critrevonc.2022.103657 |
| dewey-full |
610 |
| title_sort |
exploring biological heterogeneity and implications on novel treatment paradigm in braf-mutant metastatic colorectal cancer |
| title_auth |
Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer |
| abstract |
Approximatively 8–15% of patients with metastatic colorectal cancer (mCRC) harbor mutation in BRAF gene. Recent advances in molecular biology enabled a better knowledge of the molecular heterogeneity within BRAF mutant (BRAFMT) CRCs, including high rate of overlapping with MSI-H status and detection of non-V600E mutations related to more favorable behavior. Treatment armamentarium has been rapidly growing in this subgroup and includes targeted combinations and immunotherapy for concomitant MSI-H patients, thereby making BRAFMT mCRC an innovative model for precision oncology. Nevertheless, duration of responses to targeted strategies remains unsatisfactory due to the development of secondary resistance, which is currently the field of major clinical research on BRAFMT mCRC. This review explores the molecular, clinical and therapeutic landscape of BRAFMT mCRC as well as an update on current treatment strategies and future perspectives in light of the heterogeneity of BRAF-mutated disease. Furthermore, a novel treatment algorithm for BRAFMT mCRC will be proposed. |
| abstractGer |
Approximatively 8–15% of patients with metastatic colorectal cancer (mCRC) harbor mutation in BRAF gene. Recent advances in molecular biology enabled a better knowledge of the molecular heterogeneity within BRAF mutant (BRAFMT) CRCs, including high rate of overlapping with MSI-H status and detection of non-V600E mutations related to more favorable behavior. Treatment armamentarium has been rapidly growing in this subgroup and includes targeted combinations and immunotherapy for concomitant MSI-H patients, thereby making BRAFMT mCRC an innovative model for precision oncology. Nevertheless, duration of responses to targeted strategies remains unsatisfactory due to the development of secondary resistance, which is currently the field of major clinical research on BRAFMT mCRC. This review explores the molecular, clinical and therapeutic landscape of BRAFMT mCRC as well as an update on current treatment strategies and future perspectives in light of the heterogeneity of BRAF-mutated disease. Furthermore, a novel treatment algorithm for BRAFMT mCRC will be proposed. |
| abstract_unstemmed |
Approximatively 8–15% of patients with metastatic colorectal cancer (mCRC) harbor mutation in BRAF gene. Recent advances in molecular biology enabled a better knowledge of the molecular heterogeneity within BRAF mutant (BRAFMT) CRCs, including high rate of overlapping with MSI-H status and detection of non-V600E mutations related to more favorable behavior. Treatment armamentarium has been rapidly growing in this subgroup and includes targeted combinations and immunotherapy for concomitant MSI-H patients, thereby making BRAFMT mCRC an innovative model for precision oncology. Nevertheless, duration of responses to targeted strategies remains unsatisfactory due to the development of secondary resistance, which is currently the field of major clinical research on BRAFMT mCRC. This review explores the molecular, clinical and therapeutic landscape of BRAFMT mCRC as well as an update on current treatment strategies and future perspectives in light of the heterogeneity of BRAF-mutated disease. Furthermore, a novel treatment algorithm for BRAFMT mCRC will be proposed. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 |
| title_short |
Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer |
| url |
https://doi.org/10.1016/j.critrevonc.2022.103657 |
| remote_bool |
true |
| author2 |
Ciardiello, Davide Latiano, Tiziana Pia Maiorano, Brigida Anna Martinelli, Erika Silvestris, Nicola Ciardiello, Fortunato Maiello, Evaristo |
| author2Str |
Ciardiello, Davide Latiano, Tiziana Pia Maiorano, Brigida Anna Martinelli, Erika Silvestris, Nicola Ciardiello, Fortunato Maiello, Evaristo |
| ppnlink |
ELV019637179 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.critrevonc.2022.103657 |
| up_date |
2024-07-06T23:24:25.423Z |
| _version_ |
1803873959727333376 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV05749777X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626045229.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220808s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.critrevonc.2022.103657</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001749.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV05749777X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1040-8428(22)00081-6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Rodriquenz, Maria Grazia</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022transfer abstract</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Approximatively 8–15% of patients with metastatic colorectal cancer (mCRC) harbor mutation in BRAF gene. Recent advances in molecular biology enabled a better knowledge of the molecular heterogeneity within BRAF mutant (BRAFMT) CRCs, including high rate of overlapping with MSI-H status and detection of non-V600E mutations related to more favorable behavior. Treatment armamentarium has been rapidly growing in this subgroup and includes targeted combinations and immunotherapy for concomitant MSI-H patients, thereby making BRAFMT mCRC an innovative model for precision oncology. Nevertheless, duration of responses to targeted strategies remains unsatisfactory due to the development of secondary resistance, which is currently the field of major clinical research on BRAFMT mCRC. This review explores the molecular, clinical and therapeutic landscape of BRAFMT mCRC as well as an update on current treatment strategies and future perspectives in light of the heterogeneity of BRAF-mutated disease. Furthermore, a novel treatment algorithm for BRAFMT mCRC will be proposed.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Approximatively 8–15% of patients with metastatic colorectal cancer (mCRC) harbor mutation in BRAF gene. Recent advances in molecular biology enabled a better knowledge of the molecular heterogeneity within BRAF mutant (BRAFMT) CRCs, including high rate of overlapping with MSI-H status and detection of non-V600E mutations related to more favorable behavior. Treatment armamentarium has been rapidly growing in this subgroup and includes targeted combinations and immunotherapy for concomitant MSI-H patients, thereby making BRAFMT mCRC an innovative model for precision oncology. Nevertheless, duration of responses to targeted strategies remains unsatisfactory due to the development of secondary resistance, which is currently the field of major clinical research on BRAFMT mCRC. This review explores the molecular, clinical and therapeutic landscape of BRAFMT mCRC as well as an update on current treatment strategies and future perspectives in light of the heterogeneity of BRAF-mutated disease. Furthermore, a novel treatment algorithm for BRAFMT mCRC will be proposed.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">FDA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RCT</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">WES</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PTEN</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CARG</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ctDNA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ORR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">QoL</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BRAFMT</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CRASH</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PI3K</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">mCRC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">cfDNA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CIMP</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">WTS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">EMA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RAC1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BRAFi</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PFS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">dMMR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RNF43</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">cORR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">AE</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">OS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">DOR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CMS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MSS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">EMT</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RNAseq</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ICI</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">DCR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEK</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEKi</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MAF</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">TKI</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CDK4</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CRC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">mAbs</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NF-1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NGS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MET</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ciardiello, Davide</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Latiano, Tiziana Pia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Maiorano, Brigida Anna</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Martinelli, Erika</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Silvestris, Nicola</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ciardiello, Fortunato</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Maiello, Evaristo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Dettori, D. ELSEVIER</subfield><subfield code="t">miR-214 in stroma cells and tumor progression</subfield><subfield code="d">2016</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV019637179</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:173</subfield><subfield code="g">year:2022</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.critrevonc.2022.103657</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2016</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.52</subfield><subfield code="j">Therapie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">173</subfield><subfield code="j">2022</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.39989 |